Immunotherapy in lung cancer
1998

Immunotherapy in Lung Cancer

Editorial

Author Information

Author(s): M Al-Moundhir, M O'Brien, BE Souberbielle

Primary Institution: The Royal Marsden Hospital

Hypothesis

More research and new treatment options are needed in all stages of lung cancer.

Conclusion

Immunotherapy could play an important role in the treatment of lung cancer, especially with recent advances in technology and understanding of tumor biology.

Supporting Evidence

  • Lung cancer remains the leading cause of cancer death in Western countries.
  • About 80% of lung cancer cases are non-small-cell lung cancer (NSCLC).
  • The 5-year survival rate for NSCLC is poor, at about 12%.

Takeaway

Doctors are looking for better ways to treat lung cancer, and using the body's immune system might help fight the disease.

Methodology

The review discusses various immunotherapy mechanisms and their potential application in lung cancer treatment.

Limitations

Current treatment options for lung cancer are limited, and many trials have shown mixed or negative results.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication